Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (8.456.504 €): Risiko und Resilienz in entwicklungsbedingter Vielfalt und psychischer Gesundheit Hor 01.09.2022 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
Risiko und Resilienz in entwicklungsbedingter Vielfalt und psychischer Gesundheit
Individuals with mental health (MH) conditions and their families, especially those with highly prevalent neurodevelopmental disorders (NDDs), are exposed to high levels of discrimination and stigma, which significantly affects their physical and mental well-being. Our world-leading collaborative group at the forefront of research in NDDs will launch a new project - ?Risk, Resilience and Developmental Diversity in Mental Health? (R2D2-MH). We propose a double paradigm shift to improve the wellbeing of people with MH conditions and their families. We will move (i) from risk-focused studies towards understanding and promoting resilience, and (ii) from a diagnosis-based approach to a developmental diversity approach that will define wellbeing and functioning across the human lifespan. R2D2-MH aims to identify genetic and environmental protective/resilience factors and how they influence developmental diversity and MH. We will investigate at multiple levels two highly prevalent early risks for MH conditions: prematurity and genetic liability for NDDs. Our project has four main ambitions 1. Provide the largest European multi-scale dataset on early human brain development and MH outcomes; 2 Identify biological mechanisms of resilience to the adverse effects of NDD; 3. Co-develop, with the stakeholders, new digital tools to increase participatory research/medicine and reduce stigma; 4. Establish predictive models to guide personalised interventions. R2D2-MH integrates interdisciplinary and complementary expertise across Europe, Israel, and Australia that covers ethics, epidemiology, sociology, genetics, cell biology, neuroscience, computational modelling, Information Technology, psychology, and psychiatry. Our research is highly engaged: it embeds participant and patient involvement in research to ensure that our expected outcomes are truly translational, and will help to reduce stigma and burden for individuals with MH conditions.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Birkbeck College - University of London | ? |
| Aarhus Universitet | 351.750 € |
| Aplica Investigacion y Traslacion S. Coop. Mad | 153.187 € |
| Assistance Publique Hopitaux de Paris | 334.958 € |
| BEN-Gurion University OF THE Negev | 179.998 € |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 716.357 € |
| Fondazione Human Technopole | 500.000 € |
| Institut Pasteur | 1.114.439 € |
| Johann Wolfgang Goethe-Universitaet Frankfurt AM Main | 811.395 € |
| Karolinska Institutet | 415.050 € |
| K I Research Institute RA | 486.200 € |
| Learnenjoy | 405.225 € |
| MAX-Planck-Gesellschaft ZUR Forderung DER Wissenschaften e. V. | 355.115 € |
| PNO Innovation GmbH | 245.937 € |
| Stichting Radboud Universitair Medisch Centrum | 579.803 € |
| Tartu Ulikool | 540.000 € |
| The Provost, Fellows Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin | 429.680 € |
| Universiteit Antwerpen | 503.290 € |
| Universiteit Twente | 334.120 € |
Quelle: https://cordis.europa.eu/project/id/101057385
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: Birkbeck College, University OF London, London, Großbritannien.
